Yelena Y. Janjigian, MD, Reviews MSI as a Biomarker in for Localized Gastric Cancer

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

At the 2022 International Gastric Cancer Conference, Yelena Y. Janjigian, MD, chief of Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® about microsatellite instability (MSI) as a biomarker for patients with localized gastric cancer and how it may be effective when deciding on treatment options.


For localized therapy, the most important biomarker that we could check—and it’s critical, even though that’s a rare biomarker—is microsatellite instability, or the MSI-high population. We know that these patients tend to do very well perhaps with surgery alone or even potentially with immunotherapy and then surgery. We also know, definitively, that immunotherapy is important in those patients with stage IV disease. Whether it will have a definitive foothold in the perioperative setting is still to be determined. What we also know is that those patients’ tumors tend to be chemotherapy resistant. You may harm your patient, as a surgeon, if you don’t know what their MSI status is, and then refer them to preoperative therapy. Data from the MAGIC study shows that peri-operative [epirubicin-based] therapy harms those patients. There are plenty of data to suggest that immunotherapy helps, but chemotherapy probably harms or is neutral. There’s a suggestion that chemotherapy in adjuvant setting may be neutral, but in the preoperative setting it’s harmful.


Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531

Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content